282 related articles for article (PubMed ID: 25012446)
21. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
Soares CN; Kornstein SG; Thase ME; Jiang Q; Guico-Pabia CJ
J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
[TBL] [Abstract][Full Text] [Related]
22. A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder.
Feiger AD; Tourian KA; Rosas GR; Padmanabhan SK
CNS Spectr; 2009 Jan; 14(1):41-50. PubMed ID: 19169187
[TBL] [Abstract][Full Text] [Related]
23. Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.
Kornstein SG; Jiang Q; Reddy S; Musgnung JJ; Guico-Pabia CJ
J Clin Psychiatry; 2010 Aug; 71(8):1088-96. PubMed ID: 20797382
[TBL] [Abstract][Full Text] [Related]
24. Early improvement in depressive symptoms with desvenlafaxine 50 mg/d as a predictor of treatment success in patients with major depressive disorder.
Soares CN; Fayyad RS; Guico-Pabia CJ
J Clin Psychopharmacol; 2014 Feb; 34(1):57-65. PubMed ID: 24346751
[TBL] [Abstract][Full Text] [Related]
25. Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
Katzman MA; Nierenberg AA; Wajsbrot DB; Meier E; Prieto R; Pappadopulos E; Mackell J; Boucher M
J Clin Psychopharmacol; 2017 Oct; 37(5):555-561. PubMed ID: 28817491
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.
Septien-Velez L; Pitrosky B; Padmanabhan SK; Germain JM; Tourian KA
Int Clin Psychopharmacol; 2007 Nov; 22(6):338-47. PubMed ID: 17917552
[TBL] [Abstract][Full Text] [Related]
27. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
28. Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder.
Kornstein SG; Clayton AH; Soares CN; Padmanabhan SK; Guico-Pabia CJ
J Clin Psychopharmacol; 2010 Jun; 30(3):294-9. PubMed ID: 20473066
[TBL] [Abstract][Full Text] [Related]
29. Predictors of functional response and remission with desvenlafaxine 50 mg/d in patients with major depressive disorder.
Soares CN; Endicott J; Boucher M; Fayyad RS; Guico-Pabia CJ
CNS Spectr; 2014 Dec; 19(6):519-27. PubMed ID: 24571916
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline.
Mosca D; Zhang M; Prieto R; Boucher M
J Clin Psychopharmacol; 2017 Apr; 37(2):182-192. PubMed ID: 28146000
[TBL] [Abstract][Full Text] [Related]
31. Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Demyttenaere K; Andersen HF; Reines EH
Int Clin Psychopharmacol; 2008 Sep; 23(5):276-86. PubMed ID: 18703937
[TBL] [Abstract][Full Text] [Related]
32. Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder.
Locklear JC; Svedsäter H; Datto C; Endicott J
J Affect Disord; 2013 Jul; 149(1-3):189-95. PubMed ID: 23639212
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.
Trivedi MH; Pigotti TA; Perera P; Dillingham KE; Carfagno ML; Pitts CD
J Clin Psychiatry; 2004 Oct; 65(10):1356-64. PubMed ID: 15491239
[TBL] [Abstract][Full Text] [Related]
34. Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis.
Thase ME; Fayyad R; Cheng RF; Guico-Pabia CJ; Sporn J; Boucher M; Tourian KA
Curr Med Res Opin; 2015 Apr; 31(4):809-20. PubMed ID: 25758058
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of desvenlafaxine 50 mg/d for prevention of relapse in major depressive disorder:a randomized controlled trial.
Rosenthal JZ; Boyer P; Vialet C; Hwang E; Tourian KA
J Clin Psychiatry; 2013 Feb; 74(2):158-66. PubMed ID: 23473348
[TBL] [Abstract][Full Text] [Related]
36. Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial.
Rickels K; Montgomery SA; Tourian KA; Guelfi JD; Pitrosky B; Padmanabhan SK; Germain JM; Leurent C; Brisard C
J Clin Psychopharmacol; 2010 Feb; 30(1):18-24. PubMed ID: 20075643
[TBL] [Abstract][Full Text] [Related]
37. Desvenlafaxine 50 and 100 mg/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial.
Clayton AH; Tourian KA; Focht K; Hwang E; Cheng RF; Thase ME
J Clin Psychiatry; 2015 May; 76(5):562-9. PubMed ID: 25375652
[TBL] [Abstract][Full Text] [Related]
38. Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial.
Boyer P; Montgomery S; Lepola U; Germain JM; Brisard C; Ganguly R; Padmanabhan SK; Tourian KA
Int Clin Psychopharmacol; 2008 Sep; 23(5):243-53. PubMed ID: 18703933
[TBL] [Abstract][Full Text] [Related]
39. An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder.
Thase ME; Kornstein SG; Germain JM; Jiang Q; Guico-Pabia C; Ninan PT
CNS Spectr; 2009 Mar; 14(3):144-54. PubMed ID: 19407711
[TBL] [Abstract][Full Text] [Related]
40. Desvenlafaxine Versus Placebo in a Fluoxetine-Referenced Study of Children and Adolescents with Major Depressive Disorder.
Weihs KL; Murphy W; Abbas R; Chiles D; England RD; Ramaker S; Wajsbrot DB
J Child Adolesc Psychopharmacol; 2018 Feb; 28(1):36-46. PubMed ID: 29189044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
